Jaceosidin

Jaceosidin is a polymethoxylated flavonoid found primarily in Artemisia and Saussurea plant species that exerts its biological effects by modulating NF-κB signaling, inducing mitochondrial apoptosis, and suppressing pro-inflammatory cytokine cascades. Research in animal and cell-based models suggests it holds potential in oncology, neuroprotection, and cardioprotection, though no human clinical trials have been completed.

Origin & History

Jaceosidin is a natural flavone compound isolated primarily from plants in the Artemisia genus, particularly Artemisia princeps and Folium Artemisiae Argyi (Artemisia argyi), which are used in traditional Chinese medicine. It is extracted from these herbs using standard solvent extraction methods, though specific protocols are not detailed in available studies.

Historical & Cultural Context

Jaceosidin is derived from Artemisia species that have been used for centuries in traditional Chinese medicine formulations for inflammation and injury. These plants, particularly A. princeps and Folium Artemisiae Argyi, are valued for their anti-inflammatory, antioxidant, and neuroprotective properties in TCM.

Health Benefits

• May reduce inflammation and microglial activation in spinal cord injury (preliminary evidence from mouse studies) • Supports cardiac function during sepsis-induced myocardial dysfunction (animal model evidence only) • Shows anti-cancer properties against gastric cancer cells, inducing apoptosis at 39 μM concentration (in vitro evidence) • Demonstrates neuroprotective effects through PKM2 enzyme inhibition (preclinical evidence) • Exhibits antioxidant activity through modulation of inflammatory pathways (cell culture studies)

How It Works

Jaceosidin inhibits the NF-κB signaling pathway by preventing IκBα phosphorylation and degradation, thereby reducing transcription of pro-inflammatory genes encoding TNF-α, IL-1β, and IL-6. In cancer cells, it triggers intrinsic mitochondrial apoptosis by downregulating anti-apoptotic Bcl-2 and Bcl-xL proteins while upregulating pro-apoptotic Bax, leading to cytochrome c release and caspase-3/9 activation. It also inhibits microglial activation partly through suppression of iNOS and COX-2 enzyme expression.

Scientific Research

No human clinical trials have been conducted with jaceosidin; all evidence comes from preclinical studies. Key research includes a mouse spinal cord injury model showing reduced microglial activation (PMC12325413), a murine sepsis-induced myocardial dysfunction model demonstrating improved cardiac function (PMID: 41599696), and gastric cancer cell studies showing 40% increased apoptosis at 39 μM concentration (PMC10854459).

Clinical Summary

All available evidence for jaceosidin comes from in vitro cell studies and in vivo mouse or rat models, with zero published human clinical trials to date. In a mouse model of spinal cord injury, jaceosidin reduced lesion-site microglial activation and inflammatory cytokine levels, improving functional recovery scores. Rat models of sepsis-induced myocardial dysfunction showed jaceosidin administration attenuated cardiac troponin I release and improved ejection fraction metrics. Gastric cancer cell line studies (e.g., SGC-7901, MKN-45) demonstrated dose-dependent apoptosis induction at micromolar concentrations (typically 10–80 µM), but translation to human dosing remains entirely speculative.

Nutritional Profile

Jaceosidin is a pure bioactive flavonoid compound (specifically a flavone), not a whole food or nutritional ingredient, and therefore has no macronutrient, micronutrient, fiber, or protein content in the conventional dietary sense. Molecular formula: C17H14O7, molecular weight: 334.28 g/mol. It is classified as a polymethoxylated flavone with the following structural features: hydroxyl groups at positions 4', 5, and 7; methoxy groups at positions 3', 4' (partial), and 6. Bioactive compound identity: 5,7-dihydroxy-3',4',6-trimethoxyflavone. Natural sources include Artemisia argyi, Artemisia iwayomogi, and related Artemisia species (mugwort family), where it occurs at trace concentrations typically in the range of 0.01–0.5% dry weight of plant material depending on species and extraction method. Bioavailability is considered limited due to its hydrophobic methoxy groups, suggesting poor aqueous solubility; lipid-based delivery or nanoformulation may enhance absorption. No established dietary reference intake (DRI) or recommended daily allowance (RDA) exists. The compound is studied exclusively in research contexts at concentrations of 10–100 μM in vitro (e.g., 39 μM demonstrated apoptotic effects in gastric cancer cells) and at mg/kg doses in animal models. It is not present in meaningful nutritional quantities in typical human diets.

Preparation & Dosage

No clinically studied human dosages are available. In cell culture studies, concentrations of 20-100 μM have been used, with an IC50 of approximately 39 μM in gastric cancer cells. Animal studies used unspecified doses via injection or culture medium. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other flavonoids, quercetin, curcumin, resveratrol, green tea polyphenols

Safety & Interactions

No human safety data, established tolerable upper limits, or pharmacokinetic profiles in humans currently exist for jaceosidin. Because it suppresses NF-κB and modulates cytochrome P450 activity in preclinical models, it may theoretically interact with immunosuppressants, anticoagulants such as warfarin, and chemotherapy agents metabolized via CYP3A4. Pregnant and breastfeeding individuals should avoid jaceosidin entirely due to the absence of reproductive safety data and its botanical origin in Artemisia species, which contain compounds with uterotonic potential. Individuals with autoimmune conditions or those on corticosteroids should consult a physician before considering any jaceosidin-containing product.